CAMBRIDGE, Mass., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today reported business highlights and financial results for the second quarter ended June 30, 2017. In addition, Agios highlighted select corporate milestones and preclinical and clinical data from our clinical development programs.
“Our second quarter progress was followed by a remarkable milestone for any biotechnology company, the full approval of our first product, IDHIFA®, a treatment for patients with IDH2m R/R AML developed in partnership with Celgene,” said David Schenkein, M.D., chief executive officer at Agios.
“Our second quarter progress was followed by a remarkable milestone for any biotechnology company, the full approval of our first product, IDHIFA®, a treatment for patients with IDH2m R/R AML developed in partnership with Celgene,” said David Schenkein, M.D., chief executive officer at Agios.
